质子泵抑制剂与肝细胞癌风险之间的关联
该研究在台湾2000至2013年无病毒性肝炎的队列中开展巢式病例对照研究,纳入29473例肝细胞癌病例和294508例匹配对照。质子泵抑制剂使用与肝细胞癌的校正比值比为2.86(95%CI 2.69-3.04),并观察到累积定义日剂量分组的剂量反应效应。作者认为质子泵抑制剂可能增加肝细胞癌风险。
要点
- 在无病毒性乙肝或丙肝的患者中,质子泵抑制剂使用与肝细胞癌风险升高相关,校正比值比为2.86(95%CI 2.69-3.04)。
- 累积定义日剂量29-180、181-240、241-300和300+组较0-28组的校正比值比分别为2.74、2.98、3.23和3.43,呈剂量反应效应。
- 按肝细胞癌相关风险因素分层的亚组敏感性分析显示质子泵抑制剂使用与肝细胞癌风险的关联一致。
核心结论
- 这项观察性研究显示质子泵抑制剂可能增加肝细胞癌风险。
研究设计与样本
- 在台湾2000至2013年无病毒性肝炎的患者队列中开展巢式病例对照研究,纳入29473例肝细胞癌病例和294508例匹配对照。
主要发现
- 质子泵抑制剂使用与肝细胞癌的校正比值比为2.86(95%CI 2.69-3.04)。
- 与累积定义日剂量0-28组相比,29-180、181-240、241-300和300+组的校正比值比分别为2.74(95%CI 2.57-2.93)、2.98(95%CI 2.50-3.56)、3.23(95%CI 2.59-4.02)和3.43(95%CI 2.94-4.00)。
- 按肝细胞癌相关风险因素分层的亚组敏感性分析显示质子泵抑制剂使用与肝细胞癌风险的关联一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proton pump inhibitor (PPI) use has been reported to be associated with liver damage and might possibly be carcinogenic. AIMS: We examined whether long-term PPI use increases the risk of hepatocellular carcinoma (HCC) in patients without viral hepatitis B or C. METHODS: We conducted a nested case-control study in a cohort of patients without viral hepatitis in Taiwan from 2000 to 2013. In total, 29 473 HCC cases and 294 508 matched controls were included. Moreover, we identified prescriptions for PPI and durations between the PPI index date and cancer diagnosis date (or the corresponding date in controls). RESULTS: The adjusted odds ratio (AOR) for HCC associated with PPI use was 2.86 (95% confidence interval [CI], 2.69-3.04). Considering the use of PPIs determined according to cumulative defined daily dose (cDDD) subgroups, a dose-response effect was observed in patients exposed to 29-180, 181-240, 241-300, and 300+ cDDDs of PPIs. The AORs were 2.74 (95% CI, 2.57-2.93), 2.98 (95% CI, 2.50-3.56), 3.23 (95% CI, 2.59-4.02), and 3.43 (95% CI, 2.94-4.00) in the 29-180, 181-240, 241-300, and 300+ cDDD groups, respectively, compared with the 0-28 cDDD group. A sensitivity analysis revealed a consistent association between PPI use and the risk of HCC in subpopulations stratified by risk factors associated with HCC. CONCLUSIONS: This observational study demonstrated that PPIs might increase the risk of HCC.
引用
- Shao YJ, Chan TS, Tsai K, et al. Association between proton pump inhibitors and the risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018. PMID: 29897132. doi:10.1111/apt.14835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。